- Home
- ANGO vs TIL Comparison
ANGO vs TIL Comparison
Compare ANGO & TIL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANGO
- TIL
- Stock Information
- Founded
- ANGO 1988
- TIL 2018
- Country
- ANGO United States
- TIL United States
- Employees
- ANGO N/A
- TIL N/A
- Industry
- ANGO Medical/Dental Instruments
- TIL Biotechnology: Pharmaceutical Preparations
- Sector
- ANGO Health Care
- TIL Health Care
- Exchange
- ANGO Nasdaq
- TIL Nasdaq
- Market Cap
- ANGO 271.1M
- TIL 218.4M
- IPO Year
- ANGO 2004
- TIL 2021
- Fundamental
- Price
- ANGO $7.20
- TIL $30.84
- Analyst Decision
- ANGO Strong Buy
- TIL Buy
- Analyst Count
- ANGO 4
- TIL 4
- Target Price
- ANGO $12.00
- TIL $103.67
- AVG Volume (30 Days)
- ANGO 515.1K
- TIL 137.8K
- Earning Date
- ANGO 01-03-2025
- TIL 11-19-2024
- Dividend Yield
- ANGO N/A
- TIL N/A
- EPS Growth
- ANGO N/A
- TIL N/A
- EPS
- ANGO N/A
- TIL N/A
- Revenue
- ANGO $292,726,000.00
- TIL N/A
- Revenue This Year
- ANGO N/A
- TIL N/A
- Revenue Next Year
- ANGO $7.69
- TIL N/A
- P/E Ratio
- ANGO N/A
- TIL N/A
- Revenue Growth
- ANGO N/A
- TIL N/A
- 52 Week Low
- ANGO $5.26
- TIL $6.08
- 52 Week High
- ANGO $8.25
- TIL $92.00
- Technical
- Relative Strength Index (RSI)
- ANGO 56.31
- TIL 43.71
- Support Level
- ANGO $6.61
- TIL $24.31
- Resistance Level
- ANGO $7.46
- TIL $44.50
- Average True Range (ATR)
- ANGO 0.33
- TIL 3.59
- MACD
- ANGO 0.08
- TIL -0.28
- Stochastic Oscillator
- ANGO 73.74
- TIL 32.34
About ANGO AngioDynamics Inc.
AngioDynamics Inc designs manufactures, and sells medical, surgical, and diagnostic devices used by professional healthcare providers for the treatment of peripheral vascular disease and for use in oncology and surgical settings. Geographically, the company derives a majority of its revenue from the United States from sale of Med Tech and Med Device.
About TIL Instil Bio Inc.
Instil Bio Inc is a clinical-stage biopharmaceutical company focused on developing a cell therapy pipeline of autologous tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer. It is also engaged in developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor, or CoStAR, platform. Its pipeline includes ITIL-306 which expresses a CoStAR molecule designed to recognize FRα, a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC, and renal cancer.